Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Atrial enlargement

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    26 result(s) found for: Atrial enlargement. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2018-002541-11 Sponsor Protocol Number: P170912J Start Date*: 2019-06-06
    Sponsor Name:ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
    Full Title: Prevention of post-operative Atrial Fibrillation by BOTulinum toxin injections into epicardial fat pads around pulmonary veins in patients undergoing cardiac surgery
    Medical condition: Adult patients with indication for conventional cardiac surgery (CABG, aortic replacement, or ascending aorta surgery) will be eligible
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004865 10067824 Prophylaxis against atrial fibrillation LLT
    Population Age: Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-005844-47 Sponsor Protocol Number: D6580C00010 Start Date*: 2021-05-28
    Sponsor Name:AstraZeneca AB
    Full Title: A Randomised, Double-blind, Placebo-controlled, Multi-center Sequential Phase 2b and Phase 3 Study to Evaluate the Efficacy and Safety of AZD4831 Administered for up to 48 Weeks in Participants wit...
    Medical condition: Heart Failure with Left Ventricular Ejection Fraction > 40%
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004849 10019279 Heart failure LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) SK (Completed) CZ (Completed) DK (Completed) BG (Completed) FR (Completed) HU (Completed) PL (Completed) NL (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2017-000376-28 Sponsor Protocol Number: 1245.148 Start Date*: 2018-01-30
    Sponsor Name:Boehringer Ingelheim Limited
    Full Title: A randomised, double-blind, placebo-controlled, mechanistic cardiac magnetic resonance study to investigate the effects of empagliflozin treatment on cardiac physiology and metabolism in patients w...
    Medical condition: Chronic heart failure with reduced (HFrEF) and preserved ejection fraction (HFpEF) diagnosed at least 3 months prior to informed consent.
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004849 10008908 Chronic heart failure LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2019-002558-21 Sponsor Protocol Number: AT-001-2001 Start Date*: 2020-01-15
    Sponsor Name:Applied Therapeutics Inc.
    Full Title: Aldose Reductase Inhibition for Stabilization of Exercise capacity in Heart Failure (ARISE-HF): A Multicenter, Randomized, Placebo-Controlled Study to Evaluate the Safety and Efficacy of AT-001 in ...
    Medical condition: Diabetic Cardiomyopathy (DbCM) / Stage B Heart Failure (SBHF)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10007541 - Cardiac disorders 10012647 Diabetic cardiomyopathy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) DE (Prematurely Ended) ES (Prematurely Ended) FR (Prematurely Ended) CZ (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2018-000802-46 Sponsor Protocol Number: D169CC00001 Start Date*: 2018-09-24
    Sponsor Name:AstraZeneca AB
    Full Title: An International, Double-blind, Randomised, Placebo-Controlled Phase IIIb Study to Evaluate the Effect of Dapagliflozin on Reducing CV Death or Worsening Heart Failure in Patients with Heart Failur...
    Medical condition: Heart Failure with Preserved Ejection Fraction (HFpEF)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) NL (Completed) ES (Ongoing) PL (Completed) HU (Completed) BE (Completed) RO (Ongoing)
    Trial results: View results
    EudraCT Number: 2016-003410-28 Sponsor Protocol Number: CLCZ696D2302 Start Date*: 2017-06-05
    Sponsor Name:Novartis Pharma AG
    Full Title: A 24-week, randomized, double-blind, multi-center, parallel group, active controlled study to evaluate the effect of LCZ696 on NT-proBNP, exercise capacity, symptoms and safety compared to individu...
    Medical condition: Heart Failure with preserved Ejection Fraction (HFpEF)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004849 10019279 Heart failure LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PT (Completed) HU (Completed) LV (Completed) ES (Completed) FR (Completed) SK (Completed) CZ (Completed) GB (Completed) LT (Completed) AT (Completed) DK (Completed) BG (Completed) BE (Completed) NL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2013-001747-31 Sponsor Protocol Number: CLCZ696D2301 Start Date*: 2013-09-24
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A multicenter, randomized, double-blind, parallel group, active-controlled study to evaluate the efficacy and safety of LCZ696 compared to valsartan, on morbidity and mortality in heart failure pat...
    Medical condition: Heart failure with preserved ejection fraction
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004849 10069211 Diastolic heart failure LLT
    20.0 100000004849 10019279 Heart failure LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Completed) HU (Completed) AT (Completed) BG (Completed) DE (Prematurely Ended) ES (Completed) NO (Completed) GB (Completed) NL (Completed) CZ (Completed) IT (Completed) SE (Completed) BE (Completed) DK (Completed) GR (Completed) FI (Completed) HR (Completed) PL (Completed) SI (Completed)
    Trial results: View results
    EudraCT Number: 2018-001488-21 Sponsor Protocol Number: EST:15/17 Start Date*: 2018-11-06
    Sponsor Name:Sergio Aleman
    Full Title: EFFECT OF VITAMIN D SUPPLEMENTATION ON THE VENTRICULAR DEFORMATION RATE (STRAIN RATE) IN PATIENTS WITH HEART FAILURE WITH PRESERVED OR MODERATELY REDUCED EYECTION FRACTION
    Medical condition: Heart failure with preserved or moderately reduced eyection fraction
    Disease:
    Population Age: Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2012-001066-14 Sponsor Protocol Number: DENERVHTA Start Date*: 2012-07-17
    Sponsor Name:Consorci Mar Parc de salut de Barcelona ( Parc de Salut Mar)
    Full Title: Sympathetic renal denervation versus increment of pharmacological treatment in resistant arterial hypertension
    Medical condition: subjects with resistant hypertension
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-004072-59 Sponsor Protocol Number: 1245-0167 Start Date*: 2018-04-03
    Sponsor Name:Boehringer-Ingelheim España, S.A.
    Full Title: A phase III randomised, double-blind trial to evaluate the effect of 12 weeks treatment of once daily EMPagliflozin 10 mg compared with placebo on ExeRcise ability and heart failure symptoms, In pa...
    Medical condition: Chronic Heart Failure with preserved Ejection Fraction (HFpEF)
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Completed) GR (Completed) PT (Completed) PL (Completed) SE (Completed) NO (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2018-000298-65 Sponsor Protocol Number: BAY1021189/19334 Start Date*: 2018-06-11
    Sponsor Name:Bayer AG
    Full Title: A randomized parallel-group, placebo-controlled, double-blind, multi-center trial to eValuate the effIcacy and safeTy of the orAL sGC stImulator vericiguaT to improve phYsical functioning in activi...
    Medical condition: Heart failure and preserved ejection fraction
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004849 10008908 Chronic heart failure LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) PT (Completed) AT (Completed) ES (Completed) HU (Completed) BG (Completed) GR (Completed) PL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2016-002683-14 Sponsor Protocol Number: DSE-EDO-01-15-EU Start Date*: 2017-01-12
    Sponsor Name:Daiichi Sankyo Europe GmbH
    Full Title: Evaluation of the safety and efficacy of an edoxaban-based compared to a vitamin K antagonist-based antithrombotic regimen following successful percutaneous coronary intervention (PCI) with stent p...
    Medical condition:
    Disease: Version SOC Term Classification Code Term Level
    19.0 10007541 - Cardiac disorders 10003658 Atrial fibrillation PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) IE (Completed) GB (Completed) NL (Completed) DE (Completed) LT (Completed) ES (Completed) AT (Completed) HU (Completed) PT (Completed) BE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2021-006639-24 Sponsor Protocol Number: 2020/ABM/01/00080 Start Date*: 2022-10-19
    Sponsor Name:The Cardinal Stefan Wyszyński Institute of Cardiology
    Full Title: Multicenter Polish Study of the Use of Bromocriptine in Perinatal Cardiomyopathy. New BioMarkers in the Early Diagnosis of Peripartum CardioMyopathy. PolBrom-PPCM
    Medical condition: PeriPartum Cardiomiopathy
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: PL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2022-003111-28 Sponsor Protocol Number: REPO-HFpEF-II Start Date*: 2023-02-15
    Sponsor Name:Hospital Clínico Universitario de Valencia
    Full Title: Mechanism-based drug REpurPOsing in a subtype of Heart Failure with Preserved Ejection Fraction (REPO-HFPEF)
    Medical condition: Subtype of Heart Failure with Preserved Ejection Fraction
    Disease: Version SOC Term Classification Code Term Level
    20.0 10007541 - Cardiac disorders 10019280 Heart failures HLGT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-002278-11 Sponsor Protocol Number: 1245.110 Start Date*: 2017-06-19
    Sponsor Name:Boehringer Ingelheim International GmbH
    Full Title: A phase III randomised, double-blind trial to evaluate efficacy and safety of once daily empagliflozin 10 mg compared to placebo, in patients with chronic Heart Failure with preserved Ejection Frac...
    Medical condition: Heart failure (HF) with preserved ejection fraction (EF).
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004849 10008908 Chronic heart failure LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) HU (Completed) CZ (Completed) NL (Completed) ES (Completed) BE (Completed) GB (GB - no longer in EU/EEA) LT (Prematurely Ended) IT (Completed) RO (Completed)
    Trial results: View results
    EudraCT Number: 2017-000222-35 Sponsor Protocol Number: 2017-000222-35 Start Date*: 2017-07-21
    Sponsor Name:Medical University of Vienna
    Full Title: Effect of etelcalcetide on cardiac hypertrophy in hemodialysis patients – a randomized controlled trial
    Medical condition: Secondary hyperparathyroidism in adult patients with chronic kidney disease on hemodialysis therapy.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-003688-37 Sponsor Protocol Number: KKS-243 Start Date*: 2018-07-06
    Sponsor Name:Philipps-Universität Marburg
    Full Title: Phosphodiesterase-5 inhibition in patients with heart failure with preserved ejection fraction and combined post- and pre-capillary pulmonary hypertension (PASSION), A randomized, placebo-controll...
    Medical condition: Combined post- and pre-capillary pulmonary hypertension and heart failure with preserved ejection fraction
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004855 10077732 Pulmonary hypertension WHO functional class II LLT
    20.0 100000004849 10024106 Left heart failure LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2016-004062-26 Sponsor Protocol Number: BAY1067197/17582 Start Date*: 2017-04-06
    Sponsor Name:Bayer AG
    Full Title: A multicenter, randomized, placebo-controlled, parallel group, double blind, dose-finding Phase II trial to study the efficacy, safety, pharmacokinetic and pharmacodynamic effects of the oral parti...
    Medical condition: chronic heart failure with preserved ejection fraction (LVEF equal or above 45%)
    Disease: Version SOC Term Classification Code Term Level
    19.1 100000004849 10008908 Chronic heart failure LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) DE (Completed) ES (Completed) BG (Completed) PT (Completed) GR (Completed) AT (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2019-003626-24 Sponsor Protocol Number: MYK-491-006 Start Date*: 2020-04-06
    Sponsor Name:MyoKardia Inc.
    Full Title: An Open-Label, Exploratory Study of the Safety and Preliminary Efficacy of Danicamtiv in Stable Ambulatory Participants with Primary Dilated Cardiomyopathy Due to Either MYH7 or TTN Variants or Oth...
    Medical condition: Primary Dilated Cardiomyopathy Due to Either MYH7 or TTN Variants.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Ongoing) GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2011-001674-25 Sponsor Protocol Number: 1684-H-295 Start Date*: 2012-05-25
    Sponsor Name:Francisco J. González Vílchez
    Full Title: Evaluation of the efficacy of sildenafil on the functional capacity of patients with heart failure with preserved ejection fraction. A randomized, double blind, parallel group and placebo-controlle...
    Medical condition: Heart failure with preserved ejection fraction.
    Disease: Version SOC Term Classification Code Term Level
    14.1 10007541 - Cardiac disorders 10069211 Diastolic heart failure LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 02 08:15:58 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA